Global Acute Myeloid Testing Market, By Biomarker Type (Genetic AML Biomarker, Epigenetic AML Biomarker, Proteomic AML Biomarker), Product and Service (Services, Assay Kits), Technology (PCR, IHC, NGS, Cytogenetics, Others), End User (Clinical Laboratories, Hospitals, Academic and Research Institutes, Cancer Diagnostic Institutes, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.